|
1.
|
Coleman RE: Skeletal complications of
malignancy. Cancer. 80:1588–1594. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Mundy GR: Metastasis to bone: causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Yoneda T and Hiraga T: Crosstalk between
cancer cells and bone microenvironment in bone metastasis. Biochem
Biophys Res Commun. 328:679–687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Suva LJ, Winslow GA, Wettenhall RE, et al:
A parathyroid hormone-related protein implicated in malignant
hypercalcemia: cloning and expression. Science. 237:893–896. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Yin JJ, Selander K, Chirgwin JM, et al:
TGF-β signaling blockade inhibits PTHrP secretion by breast cancer
cells and bone metastases development. J Clin Invest. 103:197–206.
1999.
|
|
6.
|
Sanders JL, Chattopadhyay N, Kifor O,
Yamaguchi T, Butters RR and Brown EM: Extracellular calcium-sensing
receptor expression and its potential role in regulating
parathyroid hormone-related peptide secretion in human breast
cancer cell lines. Endocrinology. 141:4357–4364. 2000.
|
|
7.
|
Suda T and Takahashi N: Modulation of
osteoclast differentiation and function by the new members of the
tumor necrosis factor receptor and ligand families. Endocr Rev.
20:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Rubens RD: Clinical aspects of bone
metastases. Tumor Bone Diseases and Osteoporosis in Cancer
Patients. Body JJ: Marcel Dekker, Inc.; Brussels: 85. 2000
|
|
9.
|
Southby J, Kissin MW, Danks JA, et al:
Immunohistochemical localization of parathyroid hormone-related
protein in human breast cancer. Cancer Res. 50:7710–7716.
1990.PubMed/NCBI
|
|
10.
|
Liapis H, Crouch EC, Grosso LE, Kitazawa S
and Wick MR: Expression of parathyroidlike protein in normal,
proliferative, and neoplastic human breast tissues. Am J Pathol.
143:1169–1178. 1993.PubMed/NCBI
|
|
11.
|
Kohno N, Kitazawa S, Fukase M, et al: The
expression of parathyroid hormone-related protein in human breast
cancer with skeletal metastases. Surg Today. 24:215–220. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Downey SE, Hoyland J, Freemont AJ, Knox F,
Walls J and Bundred NJ: Expression of the receptor for parathyroid
hormone-related protein in normal and malignant breast tissue. J
Pathol. 183:212–217. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Henderson M, Danks J, Moseley J, et al:
Parathyroid hormone-related protein production by breast cancers,
improved survival, and reduced bone metastases. J Natl Cancer Inst.
93:234–237. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Linforth R, Anderson N, Hoey R, et al:
Coexpression of parathyroid hormone related protein and its
receptor in early breast cancer predicts poor patient survival.
Clin Cancer Res. 8:3172–3177. 2002.PubMed/NCBI
|
|
15.
|
Surowiak P, Dziegiel P, Matkowski R, Sopel
M, Wojnar A, Kornafel J and Zabel M: Prognostic value of
immunocytochemical determination of parathyroid hormone-related
peptide expression in cells of mammary ductal carcinoma. Analysis
of 7 years of the disease course. Virchows Arch. 442:245–251.
2003.
|
|
16.
|
Fleming NI, Trivett MK, George J, et al:
Parathyroid hormone-related protein protects against mammary tumor
emergence and is associated with monocyte infiltration in ductal
carcinoma in situ. Cancer Res. 69:7473–7479. 2009. View Article : Google Scholar
|
|
17.
|
Bouizar Z, Spyratos F, Deytieux S, de
Vernejoul MC and Jullienne A: Polymerase chain reaction analysis of
parathyroid hormone-related protein gene expression in breast
cancer patients and occurrence of bone metastasis. Cancer Res.
53:5076–5078. 1993.PubMed/NCBI
|
|
18.
|
Powell GJ, Southby J, Danks JA, et al:
Localization of parathyroid hormone-related protein in breast
cancer metastases: increased incidence in bone compared with other
sites. Cancer Res. 51:3059–3061. 1991.PubMed/NCBI
|
|
19.
|
Kohno N, Kitazawa S, Sakoda Y, Kanbara Y,
Furuya Y, Ohashi O and Kitazawa R: Parathyroid hormone-related
protein in breast cancer tissues: relationship between primary and
metastatic sites. Breast Cancer. 1:43–49. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Guise TA, Yin JJ, Taylor SD, et al:
Evidence for a causal role of parathyroid hormone-related protein
in the pathogenesis of human breast cancer-mediated osteolysis. J
Clin Invest. 98:1544–1549. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Thomas RJ, Guise TA, Yin JJ, Elliot J,
Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells
interact with osteoblasts to support osteoclast formation.
Endocrinology. 140:4451–4458. 1999.PubMed/NCBI
|
|
22.
|
Tezuka K, Onoda N, Takashima T, Ishikawa
T, Wakasa T, Wakasa K and Hirakawa K: Clinical significance of
intra-tumoral sinusoidal structures showing lympho-endothelial
immunoreactivity in breast cancer. Oncol Rep. 20:25–32. 2008.
|
|
23.
|
Henderson MA, Danks JA, Slavin JL, et al:
Parathyroid hormone-related protein localization in breast cancers
predict improved prognosis. Cancer Res. 66:2250–2256. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Torricelli C, Fortino V, Capurro E, et al:
Role of PTHrp and PTHrp-engaged pathways in MCF-7 cells
migration/invasion. Matrix Biol. 25:104–111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Dittmer A, Vetter M, Schunke D, Span PN,
Sweep F, Thomssen C and Dittmer J: Parathyroid hormone-related
protein regulates tumor-relevant genes in breast cancer cells. J
Biol Chem. 281:14563–14572. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Braun S, Vogl FD, Naume B, et al: A pooled
analysis of bone marrow micrometastasis in breast cancer. N Engl J
Med. 353:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Wulf GG, Jürgens B, Liersch T, et al:
Reverse transcriptase/polymerase chain reaction analysis of
parathyroid hormone-related protein for the detection of tumor cell
dissemination in the peripheral blood and bone marrow of patients
with breast cancer. J Cancer Res Clin Oncol. 123:514–521. 1997.
View Article : Google Scholar
|
|
28.
|
Guise TA, Kozlow WM, Heras-Herzig A,
Padalecki SS, Yin JJ and Cirgwin JM: Molecular mechanisms of breast
cancer metastases to bone. Clin Breast Cancer. 5(Suppl 2): 46–53.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Russell RG, Rogers MJ, Frith JC, et al:
The pharmacology of bisphosphonates and new insights into their
mechanisms of action. J Bone Miner Res. 14(Suppl 2): 53–65. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Gnant M: Bisphosphonates in the prevention
of disease recurrence: current results and ongoing trials. Curr
Cancer Drug Targets. 9:824–833. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Aft R, Naughton M, Trinkaus K, et al:
Effect of zoledronic acid on disseminated tumour cells in women
with locally advanced breast cancer: an open label, randomised,
phase 2 trial. Lancet Oncol. 11:421–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Saito H, Tsunenari T, Onuma E, Sato K,
Ogata E and Yamada-Okabe H: Humanized monoclonal antibody against
parathyroid hormone-related protein suppresses osteolytic bone
metastasis of human breast cancer cells derived from MDA-MB-231.
Anticancer Res. 25:3817–3824. 2005.
|
|
33.
|
Body JJ, Facon T, Coleman RE, et al: A
study of the biological receptor activator of nuclear factor-kappaB
ligand inhibitor, denosumab, in patients with multiple myeloma or
bone metastases from breast cancer. Clin Cancer Res. 12:1221–1228.
2006. View Article : Google Scholar : PubMed/NCBI
|
